Evaluation of monoclonal antibodies to human lmmunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials

Journal of Infectious Diseases

Volumn 175, Issue 5, 1997, Pages 1056-1062

  D'Souza, M Patricia ^a   Livnat, Daniella ^a   Bradac, James A ^a   Bridges, Sandra H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ADULT; ARTICLE; CHILD; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

EID: 0030985017     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516443     Document Type: Article

References (24)

1. Barbas CF III, Burton DR. Selection and evolution of high affinity human anti-viral antibodies. Trends Biotechnol 1996;14:230-4.
2. Ehrlich PH, Harfeldt KE, Justice JC, et al. Rhesus monkey responses to multiple injections of human monoclonal antibodies. Hybridoma 1987;6:151-60.
3. Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-7.
4. Trkola A, Purtscher M, Muster T, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type I. J Virol 1996;70:1100-8.
5. Muster T, Steindl F, Purtscher M, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-7.
6. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn, RA. An IgG human monoclonal antibody, which reacts with HIV-1/GP120, inhibits virus binding to cells and neutralizes infection. J Immunol 1991;146:4325-32.
7. Conley AJ, Corny MK, Kessler JA II, et al. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol 1994;68:6994-7000.
8. Laal S, Burda S, Gorny MK, Karwowska S, Buchbinder A, Zolla-Pazner S. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol 1994;68:4001-8.
9. Moore JP, Trkola A, Korber B, et al. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol 1995;69:122-30.
10. LaRosa GJ, Davide JP, Weinhold K, et al. Conserved sequence and structural elements in the IIIV-1 principal neutralizing determinant. Science 1990;249:932-5.
11. Gurgo C, Guo HG, Franchini G, et al. Envelope sequences of two new United States HIV-1 isolates. Virology 1988;164:531-6.
12. Gao F, Morrison SG, Robertson DL, et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. J Virol 1996;70:1651-67.
13. Myers G, Korber B, Wain-Hobson S, Jeang KT, Henderson LE, Pavlakis GN. Human retroviruses and AIDS. A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos, NM: Los Alamos National Laboratory, 1994.
14. WHO Network for HIV Isolation and Characterization. HIV type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral isolates. AIDS Res Hum Retroviruses 1994;10:1327-43.
15. Hinkula J, Bratt G, Gilljam G, et al. Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies. J Acquir Immune Defic Syndr 1994;7:940-51.
16. Gunthard HF, Gowland PL, Schupbach J, et al. A phase I/HA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120. J Infect Dis 1994;170:1384-93.
17. Wolfe EJ, Cavacini LA, Samore MH, et al. Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1. Clin Pharmacol Ther 1996;59:662-7.
18. Trkola A, Pomales AB, Yuan H, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69:6609-17.
19. Buchbinder A, Karwowska S, Gorny MK, Burda ST, Zolla-Pazner S. Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent isolates. AIDS Res Hum Retroviruses 1992;8:425-7.
20. Cavacini LA, Emes CL, Power J, Buchbinder A, Zolla-Pazner S, Posner MR. Human monoclonal antibodies to the V3 loop of HIV-1/gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding sites. J Acquir Immune Defic Syndr 1993;6:353-68.
21. Vijh-Warrier S, Pinter A, Honnen WJ, Tilley SA. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J Virol 1996;70:466-73.
22. Parren PWHI, Ditzel HJ, Gulizia RJ, et al. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4 binding site. AIDS 1995;9:F1-6.
23. Haigwood NL, Sutton WF, Wisher L, et al. Increased survival of SIV-infected macaques passively treated with antibody. In: Vaccines 96. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1996:225-33.
24. Gauduin MC, Allaway GP, Maddon PJ, Barbas CF III, Burton DR, Koup RA. Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules. J Virol 1996;70:2586-92.